Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 907	$ 194	$ 5,149	$ 2,153
Research and development – licenses acquired	0	0	4,230	0
General and administrative	1,161	469	3,042	1,978
Loss from operations	(2,068)	(663)	(12,421)	(4,131)
Other income (expense):
Interest income	9	1	104	4
Financing costs – warrant liabilities	0	0	(332)	0
Change in fair value of warrant liabilities	2,572	0	1,544	0
Total other income (expense)	2,581	1	1,316	4
Net income (loss)	513	(662)	(11,105)	(4,127)
Net income (loss) attributable to non-controlling interests	(13)	0	(88)	0
Net income (loss) attributable to common stockholders	$ 526	$ (662)	$ (11,017)	$ (4,127)
Net income (loss) per common share attributable to common stockholders:
Basic (in dollars per share)	$ 0.06	$ (0.45)	$ (1.54)	$ (2.86)
Diluted (in dollars per share)	$ 0.06	$ (0.45)	$ (1.54)	$ (2.86)
Basic (in shares)	8,114,155	1,465,691	7,155,050	1,441,542
Diluted (in shares)	8,200,069	1,465,691	7,155,050	1,441,542